Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “anti-”

1,068 pharma patents match "anti-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,068
Index total 30,257
Page 3 / 45

Quick answer

This filtered view shows 1,068 pharmaceutical patents matching "anti-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,068 results for “anti-” · 30,257 patents in full index Clear search

  1. US 2025222125

    Anti-FGFR2b Antibodies, Conjugates and Methods of Use

    BEIGENE LTD [KY] · Granted Jul 10, 2025 · Expires Jul 5, 2045

    granted
  2. US 12351644

    Anti-CD73 antibodies

    Corvus Pharmaceuticals, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  3. US 12344665

    Treatment of fibrodysplasia ossificans progressiva by administration of an anti-activin a antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  4. US 12344677

    Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  5. US 12338274

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  6. US 12338269

    IL-2 superagonists in combination with anti-PD-1 antibodies

    Medicenna Therapeutics Inc. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  7. US 12331107

    Methods of treating pneumonia or respiratory failure associated with COVID-19 by administering an anti-LIGHT antibody

    AVALO THERAPEUTICS, INC. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  8. US 12331127

    Therapeutic uses of anti-GITR antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  9. US 12329825

    Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject

    Dyne Therapeutics, Inc. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  10. WO 2025120867

    POLYTHÉRAPIE IMPLIQUANT DES AGENTS DE LIAISON BISPÉCIFIQUES SE LIANT À CLDN18.2 ET CD3 ET ANTICORPS ANTI-VEGFR2

    ASTELLAS PHARMA INC [JP] · Granted Jun 12, 2025 · Expires Jun 7, 2045

    granted
  11. US 12325755

    Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics

    The Regents of the University of California · Granted Jun 10, 2025 · Expires Jun 5, 2045

    granted
  12. US 12325753

    Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy

    Dyne Therapeutics, Inc. · Granted Jun 10, 2025 · Expires Jun 5, 2045

    granted
  13. US 12325750

    Anti-Dectin-2 antibodies and methods of using

    Bolt Biotherapeutics, Inc. · Granted Jun 10, 2025 · Expires Jun 5, 2045

    granted
  14. US 12319743

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject

    Dyne Therapeutics, Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  15. US 12319728

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  16. US 12319729

    Anti-Staphylococcus aureus specific antibody and nucleic acid encoding sequence thereof, and uses of the same

    China Medical University Hospital · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  17. US 12319738

    Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer

    Five Prime Therapeutics, Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  18. US 12312411

    Anti-CD38 binding domains

    Takeda Pharmaceutical Company Limited · Granted May 27, 2025 · Expires May 22, 2045

    granted
  19. US 12312391

    Anti-mutated KRAS T cell receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 27, 2025 · Expires May 22, 2045

    granted
  20. US 12303594

    Antimicrobial and anti-inflammatory compositions

    The Board of Regents of the University of Texas System · Granted May 20, 2025 · Expires May 15, 2045

    granted
  21. US 12304968

    T-cells expressing anti-LIV1 chimeric antigen receptor

    CRISPR THERAPEUTICS AG · Granted May 20, 2025 · Expires May 15, 2045

    granted
  22. US 12303724

    Non-adult human dosing of anti-CD30 antibody-drug conjugates for treatment of hematological or lymphoid cancer

    Takeda Pharmaceutical Company Limited · Granted May 20, 2025 · Expires May 15, 2045

    granted
  23. US 12291576

    Anti-CD45 antibodies and conjugates thereof

    Vor Biopharma Inc. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  24. US 12291571

    Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody

    REGENERON PHARMACEUTICALS, INC. · Granted May 6, 2025 · Expires May 1, 2045

    granted